Skip to main content
. 1999 Oct;48(4):564–572. doi: 10.1046/j.1365-2125.1999.00053.x

Figure 2.

Figure 2

Plasma concentration-time profiles of ketoconazole after single- (a) and multiple-dose (b) administration of tolterodine l-tartrate (2 mg and 1 mg twice daily, respectively) to subjects with deficient CYP2D6 activity. The identification of individual subjects is indicated in the graph.